TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04729764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 Tablet
Description: Designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the starting dose group (20mg) 8 subjects (including 2 placebo), each other 10 subjects (including Placebo (2 cases), male and female.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 Tablet
Description: Designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the starting dose group (20mg) 8 subjects (including 2 placebo), each other 10 subjects (including Placebo (2 cases), male and female.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 Tablet
Description: Designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the starting dose group (20mg) 8 subjects (including 2 placebo), each other 10 subjects (including Placebo (2 cases), male and female.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 Tablet
Description: Designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the starting dose group (20mg) 8 subjects (including 2 placebo), each other 10 subjects (including Placebo (2 cases), male and female.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 Tablet
Description: Designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the starting dose group (20mg) 8 subjects (including 2 placebo), each other 10 subjects (including Placebo (2 cases), male and female.
Study: NCT03985085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive package of sexual and reproductive health services
Description: Implementation of a comprehensive sexual and reproductive health care package for female sex workers in Côte d'Ivoire, combining an HIV PrEP offer (for HIV- FSW) with early treatment of HIV+ FSW, management of HBV infection (testing, vaccination and treatment), testing and treatment of sexually transmitted infections (STIs) and their consequences, a contraception offer, a quarterly screening of pregnancies, menstrual management counselling and identification of addiction.~This healthcare package will be available both in mobile clinics organized for a quarterly follow-up (10 intervention sites, each site being visited every two weeks) and in the fixed clinic of the partner community-based NGO, at the discretion of each female participant.
Study: NCT04598204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with oral rapmycin
Description: To treat the enrolled patients with oral rapamycin with an initial dosage of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years, and adjust the dosage to target a trough concentration of rapamycin in plasma as 10-15ng/ml （OR 15-20ng/ml if the efficacy of treatment is not satisfactory）. One course lasts for 12weeks and no more than 4 course is given.
Study: NCT01198353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: 100% of the past antipsychotic dose will be maintained in week 1, using flexible dosing of 0-100% during next 3 weeks and then discontinued. Ziprasidone will be maintained with flexible dosing of 40-160mg/day during the study period.
Study: NCT00388154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 900 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 30 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.
Study: NCT00544362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT03608540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomina
Description: Suturing system with sutures apposition then bulging then cutting
Study: NCT02918604

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: infrared technology: Veinsite
Description: peripheral vein access performed with Veinsite support by expert paediatric anaesthesiologists and intensivists

Intervention type: DEVICE
Group type: OTHER
Intervention: infrared technology: Veinsite
Description: peripheral vein access performed with Veinsite support by expert paediatric anaesthesiologists and intensivists
Study: NCT01544010

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stage Tailored Feedback Report
Description: Tailored printed feedback reports based on assessments of stages of change were delivered at baseline, 6 months and 12 months.
Study: NCT00796120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 1.5 milligram per square meter (mg/m\^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 60 or 75 mg/m\^2 will be given intravenously every 3 weeks until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Ifosfamide 6 to 9 g/m\^2 will be given intravenously every 3 weeks until disease progression.
Study: NCT01386281

Intervention type: DRUG
Intervention: E2 transdermal (Julina, BAY86-5435)
Description: Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
Study: NCT00838929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: All doses given for 3 weeks~Dose level -2 - 50 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level -1 - 100 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level I - 200 mg PO qd (initial starting dose) Dose level II - 300 mg PO qd Dose level III - 400 mg PO qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: All doses given for 3 weeks~Dose level -2 - 50 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level -1 - 100 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level I - 200 mg PO qd (initial starting dose) Dose level II - 300 mg PO qd Dose level III - 400 mg PO qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: All doses given for 3 weeks~Dose level -2 - 50 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level -1 - 100 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level I - 200 mg PO qd (initial starting dose) Dose level II - 300 mg PO qd Dose level III - 400 mg PO qd

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will take Vorinostat daily during radiation therapy, they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will take Vorinostat daily during radiation therapy, they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will take Vorinostat daily during radiation therapy, they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation.
Study: NCT00621387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofloxacin and roxithromycin
Description: 150 mg roxithromycin tablet twice daily and 200mg ofloxacin tablet twice daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets identical to ofloxacin and roxithromycin twice daily for 3 months
Study: NCT00744185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol treatment
Description: 30 days-propranolol treatment : 3 mg/kg 15 days + 4 mg/kg 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: 30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
Study: NCT01121835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PREMIXED INSULIN
Description: Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: - 30% soluble insulin aspart and 70 % protamine-crystallised insulin aspart in pre-filled Flexpen for all the countries except Mexico~* 25 % insulin lispro solution and 75% insulin lispro protamine in cartridges for Humapen Luxura for Mexico only
Study: NCT02981654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alma Lasers Pixel carbon dioxide laser system
Description: The vaginal handpiece sheath is lubricated with baby oil. Set the initial energy level (startup set up recommendations: High mode, 40 millijoule/pixel; according to the patient reaction you can increase up to 120 max. Pulse mode or Repeat mode). The handpiece is inserted as distally as possible, with the laser energy's window oriented to the 12:00 o'clock position. There are position markings on the handpiece. Trigger a laser pulse by pressing the footswitch. Shoot the laser and rotate the probe by one hour at a time. When you reach the 12:00 o'clock position again, withdrawal the headpiece back by one centimeter and repeat the rotational treatment process.
Study: NCT02092220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump with or without CGM
Study: NCT02605421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa by IV once daily for 3 doses on Days -7, -6 and -5. Given as part of Consolidation Course #1 along with Cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan by IV once daily for 3 doses on Days -8, -7, and -6. Given as part of Consolidation Course #2 along with Etoposide and Carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Melphalan and Carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Etoposide and Melphalan.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Infusion
Description: On Day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor
Description: Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF SQ or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir ANC \> 2000/μL for 3 consecutive days.
Study: NCT00461487

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control on hygiene and nutrition
Description: The active control group will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. The mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the active control on hygiene and nutrition will be delivered to the mother.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Talking Together
Description: The intervention will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. A mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. There will be three follow-up booster sessions administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
Study: NCT03975452

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced radiation volumes
Description: Patient treated with reduced radiation volumes with the exclusion of elective pelvic nodal irradiation
Study: NCT00480584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Levels 1 through 4: 1000 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Level 1: 500 mg/m\^2; Level 2: 825 mg/m\^2; Level 3: 1000 mg/m\^2; Level 4: 1250 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Levels 1 through 4: 100 mg
Study: NCT03832296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight-Loss Maintenance
Description: Over the course of the first 6-months, participants will build their self-efficacy to maintain weight loss on their own, empowered to do what is needed to achieve personal goals and long-term behavior change (months 7-18). The first 6 months of I-CAN will prepare participants for successful independent weight-loss maintenance in months 7-18. During the 12-month independent weight-loss maintenance phase participants exercise on their own and maintain their weight loss (or increase weight loss if they choose) with the only contact from interventionists being two newsletters at months 9 and 15.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (Attention Control)
Description: Participants in the control group will attend an individual session during month 1, and a monthly face-to-face group meeting during months 2-6. The sessions will provide attention, social interaction, and physician-based health education. Participants will receive a newsletter during months 9 and 15.
Study: NCT01783587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Taken orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Taken orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 15 mg/m2, given intravenously once per week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Daily, Monday-Friday, for six to seven weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Daily, Monday-Friday, for six to seven weeks
Study: NCT05679856

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated single vocal cord irradiation
Description: Only the affected vocal cord with additional margin to account for motion and setup errors will receive 58.08Gy/16 fractions using IMRT/VMAT technique

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole laryngeal radiotherapy
Description: The whole larynx from lower border of hyoid bone to lower border of cricoid cartilage will receive 63Gy/28 fractions using IMRT/VMAT technique
Study: NCT01748487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone intravitreal implant (OZURDEX)
Description: intravitreal implant
Study: NCT00822588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sangvia® System
Description: Sangvia® Intra- and Post-op System
Study: NCT04173065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK2809
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK2809
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK2809
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VK2809
Description: Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Capsule
Study: NCT04723186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT1002 for Injection
Description: MT1002 will be initiated as close to the start of PCI as possible. MT1002 should be initiated during diagnostics angiography when indication for PCI is confirmed, provided the PCI is indicated right after the coronary angiography. PCI can start after MT1002 initiation as soon as ACT is confirmed to be ≥ 200 sec or within 30 min after MT1002 starts, whichever occurs first. MT1002 will be administered by an intravenous injection of 0.90 mg/kg, 1.2 mg/kg, or 0.6 mg/kg (depending on the dose selected for the cohort) prior to the PCI procedure, immediately followed by an IV infusion of 1.8 mg/kg/hour, 2.3 mg/kg/hour, or 1.2 mg/kg/hour (depending on the dose selected for the cohort) until completion of the procedure. At completion of PCI, subjects will be continued on IV MT1002 for 4 hours from infusion start.
Study: NCT01692691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine IV - Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Carmustine IV- Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Description: Neulasta SC - Day 3
Study: NCT01562951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADALIMUMAB
Description: Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
Study: NCT02742766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008356
Description: This intervention is available as 0.5, 1, 5, and 25 mg white oral tablet. The formulation will be used to administer dose of 5 mg, 10 mg, 30 mg, 45 mg, 75 mg, 90 mg, 125 mg, 180 mg, 200 mg, and 250 mg total daily dose during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008356
Description: This intervention is available as 0.5, 1, 5, and 25 mg white oral tablet. The formulation will be used to administer dose of 5 mg, 10 mg, 30 mg, 45 mg, 75 mg, 90 mg, 125 mg, 180 mg, 200 mg, and 250 mg total daily dose during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3008356
Description: This intervention is available as 0.5, 1, 5, and 25 mg white oral tablet. The formulation will be used to administer dose of 5 mg, 10 mg, 30 mg, 45 mg, 75 mg, 90 mg, 125 mg, 180 mg, 200 mg, and 250 mg total daily dose during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.
Study: NCT02518022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin for beer
Study: NCT05198687

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long implant and partial overdentures
Description: insertion of long implants anterior to the maxillary sinus to retain partial overdentures
Study: NCT01544010

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate TTM-Tailored Feedback Report
Description: Tailored printed feedback report based on assessment of stages of change, Pros, Cons, and Temptations were delivered at baseline, 6 months and 12 months.
Study: NCT05198687

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lift and long implant
Description: performing sinus lift surgical procedure with simultaneous placement of long implants to support screw-retained prosthesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: short implant without sinus lift
Description: placement of short implants in the remaining bone above maxillary sinus to support screw-retained prosthesis without performing sinus lift

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Partial overdentures
Description: Distal extension metallic partial dentures retained by attachments to the implants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal ceramic prosthesis on long implants
Description: porcelain fused to metal fixed screw-retained prosthesis supported by long implants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal ceramic prosthesis on short implants
Description: porcelain fused to metal fixed screw-retained prosthesis supported by short implants
Study: NCT02907138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Yoga

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (physical therapy)
Study: NCT01544010

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate TTM-Tailored Feedback Report
Description: Tailored printed feedback report based on assessment of stages of change, Pros, Cons, and Temptations were delivered at baseline, 6 months and 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate TTM-Tailored Feedback Report
Description: Tailored printed feedback report based on assessment of stages of change, Pros, Cons, and Temptations were delivered at baseline, 6 months and 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full TTM-Tailored Feedback Report
Description: Tailored print feedback report based on assessment of Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full TTM-Tailored Feedback Report
Description: Tailored print feedback report based on assessment of Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.